These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8951520)

  • 1. Relaxin, a potent microcirculatory effector, is not angiogenic.
    Norrby K; Bani D; Bigazzi M; Banni Sacchi T
    Int J Microcirc Clin Exp; 1996; 16(5):227-31. PubMed ID: 8951520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-8 and de novo mammalian angiogenesis.
    Norrby K
    Cell Prolif; 1996 Jun; 29(6):315-23. PubMed ID: 8809123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor and de novo mammalian angiogenesis.
    Norrby K
    Microvasc Res; 1996 Mar; 51(2):153-63. PubMed ID: 8778571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin.
    Norrby K; Ostergaard P
    Int J Microcirc Clin Exp; 1996; 16(1):8-15. PubMed ID: 8739219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis.
    Norrby K; Ostergaard P
    Int J Microcirc Clin Exp; 1997; 17(6):314-21. PubMed ID: 9527522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-1-alpha and de novo mammalian angiogenesis.
    Norrby K
    Microvasc Res; 1997 Jul; 54(1):58-64. PubMed ID: 9245645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NO and de novo mammalian angiogenesis: further evidence that NO inhibits bFGF-induced angiogenesis while not influencing VEGF165-induced angiogenesis.
    Näslund I; Norrby K
    APMIS; 2000 Jan; 108(1):29-37. PubMed ID: 10698082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.
    Zhou X; Chen X; Cai JJ; Chen LZ; Gong YS; Wang LX; Gao Z; Zhang HQ; Huang WJ; Zhou H
    Drug Des Devel Ther; 2015; 9():4599-611. PubMed ID: 26316699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide suppresses bFGF- and IL-1-alpha-mediated but not VEGF165-mediated angiogenesis in natively vascularized mammalian tissue.
    Norrby K
    APMIS; 1998 Dec; 106(12):1142-8. PubMed ID: 10052722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of rat skin flap viability by relaxin-expressing adenovirus.
    Lee WJ; Yun CO; Yun IS; Kim YO; Choi IK; Yun TJ; Rah DK
    Wound Repair Regen; 2011 Nov; 19(6):709-17. PubMed ID: 22092841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic fibroblast growth factor and de novo mammalian angiogenesis.
    Norrby K
    Microvasc Res; 1994 Jul; 48(1):96-113. PubMed ID: 7527478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis.
    Norrby K
    Microvasc Res; 1998 Jan; 55(1):43-53. PubMed ID: 9473408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB.
    Dschietzig T; Bartsch C; Richter C; Laule M; Baumann G; Stangl K
    Circ Res; 2003 Jan; 92(1):32-40. PubMed ID: 12522118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis.
    Ho TY; Santora K; Chen JC; Frankshun AL; Bagnell CA
    Bone; 2011 Jun; 48(6):1346-53. PubMed ID: 21419242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relaxin (RLX) and estrogen affect estrogen receptor alpha, vascular endothelial growth factor, and RLX receptor expression in the neonatal porcine uterus and cervix.
    Yan W; Chen J; Wiley AA; Crean-Harris BD; Bartol FF; Bagnell CA
    Reproduction; 2008 May; 135(5):705-12. PubMed ID: 18304981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of relaxin in two models of renal mass reduction.
    Garber SL; Mirochnik Y; Brecklin C; Slobodskoy L; Arruda JA; Dunea G
    Am J Nephrol; 2003; 23(1):8-12. PubMed ID: 12373075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of relaxin against cisplatin-induced nephrotoxicity in rats.
    Yoshida T; Kumagai H; Kohsaka T; Ikegaya N
    Nephron Exp Nephrol; 2014; 128(1-2):9-20. PubMed ID: 25403022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The local administration of relaxin induces changes in the microcirculation of the rat mesocaecum.
    Bigazzi M; Del Mese A; Petrucci F; Casali R; Novelli GP
    Acta Endocrinol (Copenh); 1986 Jun; 112(2):296-9. PubMed ID: 3739555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes.
    Wong SE; Samuel CS; Kelly DJ; Zhang Y; Becker GJ; Hewitson TD
    Protein Pept Lett; 2013 Sep; 20(9):1029-38. PubMed ID: 23343143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of relaxin on the microvasculature of mouse mammary gland.
    Bani G; Bani Sacchi T; Bigazzi M; Bianchi S
    Histol Histopathol; 1988 Oct; 3(4):337-43. PubMed ID: 2980242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.